Source: Eur Respir J, 57 (6) 2003502; 10.1183/13993003.03502-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Jonathan L. Gillan, Donald J. Davidson, Robert D. Gray. Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages. Eur Respir J, 57 (6) 2003502; 10.1183/13993003.03502-2020

Member's Comments

No comment yet.

Related content which might interest you: Targeting CFTR as a therapy for cystic fibrosis Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies Source: Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016 Year: 2017 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 New insights into the pathophysiology of lung disease in cystic fibrosis patients Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1 Year: 2006 LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Accumulation of mast cell subtypes in areas of remodeling in COPD and cystic fibrosis Source: Annual Congress 2008 - Basic science in asthma and COPD Year: 2008 Mechanisms and markers of airway inflammation in cystic fibrosis Source: Eur Respir J 2002; 19: 333-340 Year: 2002 Peptide transport mechanisms in cystic fibrosis and normal human lung Source: Eur Respir J 2001; 18: Suppl. 33, 76s Year: 2001 Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019 Year: 2020 Cross-talk of inflammatory mediators and airway epithelium reveals the cystic fibrosis transmembrane conductance regulator as a major target Source: ERJ Open Res, 7 (4) 00247-2021; 10.1183/23120541.00247-2021 Year: 2021 Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021 Year: 2022 Distribution and characterisation of lung mast cells in cystic fibrosis Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009 CFTR: cystic fibrosis and beyond Source: Eur Respir J 2014; 44: 1042-1054 Year: 2014 Lung inflammation in cystic fibrosis: an overlooked therapeutic target? Source: Virtual Congress 2020 – Cystic fibrosis: from cradle to old age Year: 2020 Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis Source: Eur Respir J, 57 (1) 1902426; 10.1183/13993003.02426-2019 Year: 2021 Characterization of cystic fibrosis airway epithelium in vitro Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Regulation of interleukin-8 by miR-17 during chronic inflammation in cystic fibrosis Source: International Congress 2015 – The multiple faces of host defense Year: 2015 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020 Year: 2020